*Casey Eye Institute, Oregon Health & Science University, Portland, Oregon;

†Department of Ophthalmology, Aichi Medical University, Nagakute, Japan; and

‡Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon 97239.

Reprint requests: Steven T. Bailey, MD, Casey Eye Institute, Oregon Health & Science University, 515 SW Campus Dr., Portland, OR 97239; e-mail: [email protected]

Supported by the National Institutes of Health (R01EY027833, R01EY024544, P30EY010572); William and Mary Greve Special Scholar Award, and unrestricted departmental funding from the Research to Prevent Blindness (New York, NY). The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Presented at ARVO2021 in virtual meeting at May 1 2021.

None of the authors has any financial/conflicting interests to disclose.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.retinajournal.com).

Oregon Health & Science University (OHSU) and Drs. Jia, Huang, and Bailey have a significant financial interest in Optovue Inc, a company that may have a commercial interest in the results of this research and technology. These potential conflicts of interest have been reviewed and managed by the OHSU. Dr Tsuboi reported receiving personal fees from Bayer, Novartis Pharma, Santen, and Alcon Japan outside the submitted work. Dr. Kamei has a financial interest (to institution) in HOYA Surgical Optics, Abbott Medical Optics, Novartis Pharma KK, Pfizer Japan, Inc., HANDAYA Co., Ltd., TOMEY Co., Ltd., Kowa Co., Ltd, Santen Co., Ltd., Senju Co., Ltd., Otsuka Co., Ltd., and Alcon Japan Ltd. outside the submitted work. No other disclosures were reported.